The U.S. House Committee on Oversight and Accountability last week launched an investigation into how “anticompetitive tactics” by the three largest pharmacy benefit managers—Express Scripts, CVS Caremark, and OptumRx—are driving up healthcare costs and hurting patient care within federal health care programs.
Committee Chair James Comer’s (R-Ky.) March 1 announcement does not mention the 340B program. The government probe however comes amid a wave of legislation recently introduced in a number of states targeting PBM policies that discriminate against 340B covered entities and/or their contract pharmacies, such as reimbursing them at a lower rate compared with non-340B entities.
The U.S. House Committee on Oversight and Accountability last week launched an investigation into how “anticompetitive tactics” by the three largest pharmacy benefit managers—Express Scripts, CVS Caremark, and OptumRx—are driving up healthcare costs and hurting patient care within federal health care programs.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
